Babak Moein attends patients regularly who have had lipedema for years, without ever being aware of the condition
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity
Current availability is confined to the research-chemical market, without regulatory oversight or established human safety data
Clients who have a history of the following SHOULD NOT take Semaglutide:: Type I diabetes A history of pancreatitis (inflammation of the pancreas) Active suicidal thoughts A history of allergic reaction to any of the components of semaglutide A personal or family history of medullary thyroid carcinoma A personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2) Patients who are currently pregnant, may become pregnant, or breastfeeding
The SURMOUNT-5 trial directly compared tirzepatide against semaglutide for obesity treatment, with tirzepatide achieving 20.2% weight loss versus 13.7% for semaglutide at their respective maximum tolerated doses
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial
